Pharma 2020: Taxing times ahead
View this page in: 中文We discussed many of the far-reaching changes influencing the pharmaceutical and life sciences industry (Pharma) as it approaches the second decade of the new millennium in the previous four papers in the PricewaterhouseCoopers’Pharma 2020 series. Our latest report focuses on the resulting opportunities and challenges from a tax perspective.
It builds on the fourth paper in the series, “Pharma 2020: Challenging business models”, in which we argued that many companies will have to adopt a more collaborative approach...
